Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.46
+0.03000.36%
Post-market: 8.43-0.0300-0.35%19:59 EDT
Volume:4.30M
Turnover:36.26M
Market Cap:760.86M
PE:-9.01
High:8.46
Open:8.42
Low:8.42
Close:8.43
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Chimerix Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
24 Feb

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.
·
22 Feb

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
19 Feb

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
19 Feb

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise

MT Newswires Live
·
18 Feb

Chimerix Shares Touch 52-Week High on Speedy FDA Review of Brain Tumor Treatment

Dow Jones
·
18 Feb

Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating

MT Newswires Live
·
18 Feb

Chimerix Inc : TD Cowen Raises Target Price to $12 From $8

THOMSON REUTERS
·
18 Feb

Chimerix Inc : Wedbush Raises Target Price to $7 From $6

THOMSON REUTERS
·
18 Feb

BRIEF-Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone

Reuters
·
18 Feb

Chimerix’s NDA for dordaviprone accepted by FDA

TIPRANKS
·
18 Feb

Chimerix Inc - No Advisory Committee Meeting Planned for Chimerix's Dordaviprone Nda

THOMSON REUTERS
·
18 Feb

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27m-Mutant Diffuse Glioma

THOMSON REUTERS
·
18 Feb

Chimerix Inc - FDA Grants Priority Review to Chimerix's Dordaviprone, Pdufa Date August 18, 2025

THOMSON REUTERS
·
18 Feb